CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on enhancing allogeneic hematopoietic stem cell transplantation (HSCT) for patients with high-risk hematological tumors. It aims to develop innovative cell selection processes to create targeted T cell products that improve patient outcomes and reduce complications like graft-versus-host disease.
Patients with high-risk hematological tumors can be cured by allogeneic hematopoietic stem cell transplantation (HSCT).
However, the main causes of failure of HSCT are infections, tumor relapse and over-shooting immune responses of the donor T cells to healthy cells and tissues of the patient or graft-versus host disease (GvHD).
Therefore, this treatment is still associated with a high morbidity and mortality, as well as a high economic burden.
Our previous EU FP6 project, ALLOSTEM, resulted in…
KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT
UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, GOETTINGEN
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Leiden University Medical Center
Netherlands, Leiden
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Germany, Muenchen
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
